MedTrace Logo

To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.

NCT02394093 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-09-19

No results posted yet for this study

Summary

To evaluate the bioavailability of a single oral dose of the Acetylsalicylic Acid containing dry powder 500 mg in comparison to the bioavailability of a single oral dose of aspirin tablets and aspirin effervescent tablets in healthy adults.

Conditions

  • Pharmacology, Clinical

Interventions

DRUG

Aspirin (Acetylsalicylic acid, BAYe4465)

One stick pack containing 500 mg acetylsalicylic acid dry powder

DRUG

Aspirin (Acetylsalicylic acid, BAYe4465)

One tablet containing 500 mg acetylsalicylic acid

DRUG

Aspirin (Acetylsalicylic acid, BAYe4465)

One effervescent tablet containing 500 mg acetylsalicylic acid

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02394093 on ClinicalTrials.gov